PF-Atlas › Clinical Trials › NCT01225211

Study of VX-809 Alone and in Combination With VX-770 in Cystic Fibrosis Patients Homozygous or Heterozygous for the F508del-CFTR Mutation

Lumacaftor · Phase 2

Registry ID

NCT01225211

Phase

Phase 2

Status

Completed

Drug / intervention

Lumacaftor

Sponsor

Vertex Pharmaceuticals Incorporated

Start

2010-10

Enrollment

312

Locations

About this trial

The purpose of this study is to evaluate of the safety, efficacy, pharmacokinetics (PK) and pharmacodynamic (PD) effects of lumacaftor (VX-809) alone and when coadministered with ivacaftor (VX-770) in participants with cystic fibrosis, homozygous or heterozygous for the F508del-CFTR mutation.

View NCT01225211 on ClinicalTrials.gov →

Explore related

All Lumacaftor trials All IPF trials

Medical disclaimer. This page summarizes public trial data for NCT01225211 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.